Hannan Cathal J, Lewis Daniel, O'Leary Claire, Donofrio Carmine A, Evans Dafydd G, Stapleton Emma, Freeman Simon R, Lloyd Simon K, Rutherford Scott A, Hammerbeck-Ward Charlotte, Brough David, Allan Stuart M, Coope David, King Andrew T, Pathmanaban Omar N
Surgical Neuro-Oncology Manchester (SNO-MAN) Laboratory, Manchester Centre for Clinical Neurosciences, Salford Royal Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom.
Manchester Centre for Clinical Neurosciences, Salford Royal Foundation Trust, Manchester, United Kingdom.
J Neurol Surg B Skull Base. 2020 Sep 10;83(1):1-10. doi: 10.1055/s-0040-1716688. eCollection 2022 Feb.
Vestibular schwannomas (VS) are histologically benign tumors arising from cranial nerve VIII. Far from a homogenous proliferation of Schwann cells, mounting evidence has highlighted the complex nature of the inflammatory microenvironment in these tumors. A review of the literature pertaining to inflammation, inflammatory molecular pathways, and immune-related therapeutic targets in VS was performed. Relevant studies published up to June 2020 were identified based on a literature search in the PubMed and MEDLINE databases and the findings were synthesized into a concise narrative review of the topic. The VS microenvironment is characterized by a dense infiltrate of inflammatory cells, particularly macrophages. Significantly higher levels of immune cell infiltration are observed in growing versus static tumors, and there is a demonstrable interplay between inflammation and angiogenesis in growing VS. While further mechanistic studies are required to ascertain the exact role of inflammation in angiogenesis, tumor growth, and Schwann cell control, we are beginning to understand the key molecular pathways driving this inflammatory microenvironment, and how these processes can be monitored and targeted in vivo Observational research has revealed a complex and heterogeneous tumor microenvironment in VS. The functional landscape and roles of macrophages and other immune cells in the VS inflammatory infiltrate are, however, yet to be established. The antiangiogenic drug bevacizumab has shown the efficacy of targeted molecular therapies in VS and there is hope that agents targeting another major component of the VS microenvironment, inflammation, will also find a place in their future management.
前庭神经鞘瘤(VS)是起源于第八对颅神经的组织学良性肿瘤。与施万细胞的同质增殖不同,越来越多的证据凸显了这些肿瘤中炎症微环境的复杂性。
对有关VS炎症、炎症分子途径和免疫相关治疗靶点的文献进行了综述。通过在PubMed和MEDLINE数据库中进行文献检索,确定了截至2020年6月发表的相关研究,并将研究结果综合成一篇关于该主题的简明叙述性综述。
VS微环境的特征是炎症细胞,特别是巨噬细胞的密集浸润。在生长中的肿瘤与静止性肿瘤中观察到免疫细胞浸润水平显著更高,并且在生长中的VS中炎症与血管生成之间存在明显的相互作用。虽然需要进一步的机制研究来确定炎症在血管生成、肿瘤生长和施万细胞控制中的确切作用,但我们开始了解驱动这种炎症微环境的关键分子途径,以及如何在体内监测和靶向这些过程。
观察性研究揭示了VS中复杂且异质性的肿瘤微环境。然而,巨噬细胞和其他免疫细胞在VS炎症浸润中的功能格局和作用尚未明确。抗血管生成药物贝伐单抗已显示出靶向分子疗法在VS中的疗效,并且有望靶向VS微环境另一个主要成分——炎症的药物也将在其未来治疗中占有一席之地。